



Drug Resistance Against Cancer Treatment

Guest Editor:

**Dr. Hamidreza Montazeri
Aliabadi**

Department of Biomedical and
Pharmaceutical Sciences,
Chapman University School of
Pharmacy, Harry and Diane
Rinker Health Science Campus,
Irvine, CA 92618, USA

Deadline for manuscript
submissions:

25 September 2024

Message from the Guest Editor

In the era when chemotherapy was the only option for “drug” therapy in cancer treatment, multidrug resistance (MDR) was a major hurdle that could suddenly render even the most effective treatments obsolete. In fact, MDR seemed to be so inevitable that it was known as a matter of “when”, rather than a matter of “if”. Chemotherapy is still at the forefront of cancer treatment, even following the introduction of molecularly targeted small molecule drugs. While mechanisms involved in MDR might not apply to molecularly targeted drugs, the resistance to these drugs is also an ever-present threat. However, just like the drug itself, the resistance mechanisms (inherent or acquired) are more specific, often relating to the same signaling pathway that is the target of the drug.

This Special Issue aims to include research and review papers that provide the most recent information and developments on the ongoing battle with resistance against cancer treatment. The scope of the issue is to cover both MDR and resistance against molecularly targeted drugs. Our hope is to bring together a collective wisdom regarding our approach to drug resistance in cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e
Bioquímica (DQB) e Centro de
Química Estrutural (CQE),
Institute of Molecular Sciences,
Faculdade de Ciências,
Universidade de Lisboa, Lisboa,
Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com